Used in the treatment of certain cancers, particularly in hematologic malignancies such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). It targets the CXCR4 receptor, which plays a key role in cancer cell migration, survival, and resistance to therapy. By blocking CXCR4, it disrupts the interaction between cancer cells and the protective bone marrow microenvironment, making cancer cells more susceptible to chemotherapy and reducing their ability to spread. Also investigated for use in stem cell mobilization, helping to release hematopoietic stem cells from the bone marrow into the bloodstream for collection and transplantation. Shows potential in combination therapies to improve treatment outcomes in aggressive or relapsed cancers.